COMMUNIQUÉS West-GlobeNewswire
-
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
16/04/2026 -
Wellcome Leap Announces $2 Million Prize in $50 Million Quantum for Bio Challenge Program
16/04/2026 -
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
16/04/2026 -
Medera Receives FDA Fast Track Designation for Gene Therapy Targeting Duchenne Muscular Dystrophy-Associated Cardiomyopathy
16/04/2026 -
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
16/04/2026 -
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026
16/04/2026 -
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
16/04/2026 -
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
16/04/2026 -
Hemp Hop’s First 420 Deals in Houston, TX - Buy 3 Get 1 Free 2026
16/04/2026 -
EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026
16/04/2026 -
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
16/04/2026 -
Kane Biotech Presents revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference
16/04/2026 -
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
16/04/2026 -
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
16/04/2026 -
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
16/04/2026 -
ATUM Welcomes Gavin Barnard, Ph.D., as Chief Scientific Officer
16/04/2026 -
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
16/04/2026 -
Soleo Health Appoints Joy Rowan as New Senior Vice President of Sales to Drive Strategic Growth Initiatives
16/04/2026 -
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
16/04/2026
Pages